Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas

Metastatic Pancreatic Cancer Clinical Trial

Official title:

Feasibility of Biodynamic Imaging for Predicting Effect of Gemcitabine and Nab-paclitaxel on Metastatic Adenocarcinoma of the Pancreas

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02205788
• Other study ID #: IUCRO-0479
• Secondary ID: 1405049285
• Status: Withdrawn
• Start date: July 2014
• Est. completion date: September 14, 2016

Study information

• Verified date: July 2019
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine if you can use an assay on tumor samples to see different patterns in response to the same chemotherapy treatment.

Description:

To examine the feasibility of using biodynamic imaging (BDI) as a chemosensitivity assay on fresh tumor samples obtained by core needle biopsy from patients planned to receive routine care gemcitabine and nab-paclitaxel for treatment of metastatic adenocarcinoma of the pancreas.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 14, 2016
• Est. primary completion date: September 14, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ability to understand and willingness to sign an informed consent and authorization for release of health information for research

2. = 18 years old at time of consent

3. Patients with a diagnosis of metastatic pancreatic cancer (mPC) who have not received prior combination chemotherapy. Exception: prior adjuvant chemoradiation with fluorouracil or gemcitabine is allowed.

4. Patients considered for routine care treatment with gemcitabine and nab-paclitaxel (allowed to receive other experimental therapy with gem/nab backbone if participating in another clinical trial)

5. Measurable disease by RECIST v1.1 criteria

6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1

7. Willingness to undergo transcutaneous core needle biopsy of metastatic tumor for research purposes

8. Women are eligible to participate if they are of non-childbearing potential or have documentation of a negative pregnancy test (serum or urine ß-hCG) within 1 week of the start of protocol treatment.

9. Women and men of childbearing potential must agree to use adequate, highly effective contraceptive measures during protocol treatment

10. Laboratory values: Platelets = 100 K/mm3 international normalized ratio (INR) < 1.2, Partial thromboplastin time (PTT) in normal range, Cr < 2.0, Total bilirubin < 2 times upper limit normal (ULN), transaminases < 5 times ULN

Exclusion Criteria:

1. History of abnormal bleeding with minor procedures or documented platelet aggregation disorder such as VonWillebrand disease

2. Women who are pregnant or breastfeeding

Related Conditions & MeSH terms

• Adenocarcinoma
• Metastatic Pancreatic Cancer
• Pancreatic Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Patrick Joseph Loehrer Sr.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BDI as a chemosensitivity assay on fresh tumor samples	To examine the feasibility of using BDI as a chemosensitivity assay on fresh tumor samples obtained by core needle biopsy from patients planned to receive routine care gemcitabine and nab-paclitaxel for treatment of metastatic adenocarcinoma of the pancreas.	up to 336 days
Secondary	BDI patterns and results with Response Evaluation Criteria	To compare BDI patterns consistent with chemotherapy response ex-vivo to response to chemotherapy as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.	up to 336 days